Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ECG (Electrocardiography) and cardiac damage markers in NICE (UK National Institute for Clinical Excellence) guidelines:

This article was originally published in Clinica

Executive Summary

Electrocardiography and/or blood testing are set to become a requirement for deciding on the use of a combination of drugs to treat non-ST-segment-elevation acute coronary syndrome in people at moderate-to-high risk of myocardial infarction (MI) or death in the UK. The final draft of forthcoming guidelines by the National Institute for Clinical Excellence (NICE) on the use of clopidogrel in combination with aspirin requires that MI care policy be based on tests, such as ECG, to assess ischaemia and/or the presence of raised levels of cardiac cell damage markers, such as troponin. There were over 112,000 recorded cases of MI among over 153,000 cases of angina (including over 88,000 of unstable angina) in England and Wales in 2002-03. The exact incidence of non-ST-segment-elevation acute coronary syndrome is, however, difficult to estimate, says NICE. The 15-day final appeal period for this appraisal ends on May 14.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts